Gut microbiome of gastroenterological cancer: An exhaustive prospective cohort study

Gut microbiome of gastroenterological cancer: An exhaustive prospective cohort study - Gut microbiome of gastroenterological cancer: An exhaustive prospective cohort study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038703

Enrollment

100

Registered

2019-11-30

Start date

2019-10-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroenterological cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: over 18-year-old confirming gastroenterological cancer pathologically patients were recieved informed consent

Exclusion criteria

Exclusion criteria: judgement not to register suitably

Design outcomes

Primary

Measure	Time frame
To estimate 5-year overall survival in the difference of gut microbiome in gastroenterological cancer.	—

Secondary

Measure	Time frame
To evaluate the association between surgical outcomes and microbiome in the case of gastroenterological cancer To evaluate the association between the efficacy of preoperative or postoperative treatment and microbiome in the case of gastroenterological cancer To evaluate the association between surgical outcomes and microbiome in the case of gastroenterological cancer To evaluate the perioperative complication To evaluate the tumor infiltrating lymphocytes around the cancer and to investigate the association to microbiota, DNA, RNA or metabolite To evaluate the association between the postoperative complication and microbiota, DNA, RNA or metabolite To evaluate the association between complication and risk factor during preoperative treatment To evaluate the surgical outcomes according to final tumor stages To evaluate the association between the treatment outcome according to patient background and microbiota, DNA, RNA or metabolite To evaluate the association among microbiota, DNA, RNA or metabolite in the cancer tissue, oral mucosa or blood tissue. To evaluate to compare the microbiota, DNA, RNA or metabolite between part of cancer tissue and that of normal tissue. To evaluate to compare the metabolite such as sulfur metabolite, lipid metabolite, sugar metabolite between part of cancer tissue and that of normal tissue. To evaluate postoperative endoscopic polypectomy and association to microbiota, DNA, RNA or metabolite in the case of gastroenterological cancer surgery. To evaluate the recurrence patterns and long-term outcomes and to investigate the association to microbiota, DNA, RNA or metabolite in the case of recurrence after gastroenterological cancer surgery.	—

Measure

Time frame

To evaluate the association between surgical outcomes and microbiome in the case of gastroenterological cancer To evaluate the association between the efficacy of preoperative or postoperative treatment and microbiome in the case of gastroenterological cancer To evaluate the association between surgical outcomes and microbiome in the case of gastroenterological cancer To evaluate the perioperative complication To evaluate the tumor infiltrating lymphocytes around the cancer and to investigate the association to microbiota, DNA, RNA or metabolite To evaluate the association between the postoperative complication and microbiota, DNA, RNA or metabolite To evaluate the association between complication and risk factor during preoperative treatment To evaluate the surgical outcomes according to final tumor stages To evaluate the association between the treatment outcome according to patient background and microbiota, DNA, RNA or metabolite To evaluate the association among microbiota, DNA, RNA or metabolite in the cancer tissue, oral mucosa or blood tissue. To evaluate to compare the microbiota, DNA, RNA or metabolite between part of cancer tissue and that of normal tissue. To evaluate to compare the metabolite such as sulfur metabolite, lipid metabolite, sugar metabolite between part of cancer tissue and that of normal tissue. To evaluate postoperative endoscopic polypectomy and association to microbiota, DNA, RNA or metabolite in the case of gastroenterological cancer surgery. To evaluate the recurrence patterns and long-term outcomes and to investigate the association to microbiota, DNA, RNA or metabolite in the case of recurrence after gastroenterological cancer surgery.

—

Countries

Japan

Contacts

Public ContactMiyuki Onodera

Yokohama city university Ethics Committee for Medical Research Involving Human Subjects

rinri@yokohama-cu.ac.jp0457872650

Outcome results